Introduction
The promyelocytic leukemia (PML) gene is frequently involved in the t(15;17) chromosomal translocation of acute promyelocytic leukemia (APL), a subtype of myeloid leukemia. The PML gene was initially cloned as the t(15;17) chromosomal translocation partner of RARa in APL patients (de The et al., 1991; Goddard et al., 1991; Zhong et al., 2000b; Salomoni and Pandolfi, 2002) . Because the translocation takes place in only one allele, the APL blast still carries one wild-type allele of both genes, PML and RARa (Pandolfi, 2001; Salomoni and Pandolfi, 2002) . The PML protein is typically found in distinct subnuclear dotted structures along with other proteins. These speckled macromolecular structures are hallmark of PML bodies. In normal cells, 20-30 of these PML bodies are found per nucleus, with diameters between 0.2 and 1 mm, which could vary during cell cycle (Zhong et al., 2000a, b; Salomoni and Pandolfi, 2002) . However, in APL blasts, PML, together with other proteins are delocalized from the PML bodies into aberrant micro-speckled nuclear structures. In APL blasts, the fusion protein PML-RARa causes disruption of the architecture of PML bodies through direct physical association, a phenotype reversed by treatment with all trans retinoic acid (ATRA) (Zhong et al., 2000b) . ATRA causes degradation of PML-RARa and corresponding relocalization of the various PML body constituents into macromolecular structure (Zhu et al., 1999; Lallemand-Breitenbach et al., 2001; Zhu et al., 2001) . Consistent with these observations, it has also been shown in transgenic mice that while PML-RARa causes leukemia with APL-like features, the dominantnegative RARa mutants fail to do so (Pandolfi, 2001; Salomoni and Pandolfi, 2002) . These observations underscore the functional importance of PML-RARa and disruption of PML bodies in leukemogenesis. PML acts as coactivator of RARa, and thereby also contributes to differentiation of myelod precursor cells (Wang et al., 1998a) . Besides its role as a tumor suppressor, PML is shown to be a pro-apoptotic factor since it participates in several apoptotic pathways (Quignon et al., 1998; Wang et al., 1998b; Guo et al., 2000; Lunghi et al., 2005) .
Biochemical identification of several transcription factors and chromatin modifying enzymes associated with PML bodies suggest that the PML bodies may act as store-house for transcription factors and that both the activities and/or local concentrations of these factors may be modulated by their association with PML bodies (Zhong et al., 2000b; Salomoni and Pandolfi, 2002) . The sequence analysis of PML reveals that it has a characteristic RING finger motif, often found in transcription factors. Although PML does not appear to bind DNA in a sequence-specific fashion, it possesses a cryptic transcription activation domain that is dependent on the integrity of the RING finger. In contrast, the full-length PML protein inhibits transcription (Zhong et al., 2000b) . The function of PML-RARa as a transcription factor is better studied. PML-RARa fusion protein maintains both the ligand responsiveness and DNA binding domains of retinoic acid receptor (RAR), producing a deregulated transcription factor (Zhong et al., 2000b) . But at the same time, the fusion protein also exhibits higher affinity for histone deacetylases (HDACs), so that a high dose of ATRA is needed to dissociate HDACs from PML-RARa and to induce the degradation of PML-RARa (Lin et al., 1998; Altucci and Gronemeyer, 2001) . The consequence of the formation of PML-RARa is a block of differentiation at the promyelocytic stage. Because HDACs are potent transcriptional co-repressors (Lin et al., 1998; Cress and Seto, 2000; Lin and Evans, 2000; Marmorstein, 2001; Narlikar et al., 2002; Hake et al., 2004) , HDAC dependent gene silencing of normal retinoid signaling during myelopoiesis may cause the differentiation block.
In contrast, it is likely that the altered function of PML in the fusion protein such as the loss of its proapoptotic activity (Quignon et al., 1998; Wang et al., 1998b; Lunghi et al., 2005) , or abrogation of co-repressor function, adds to the growth potential or survival capacity of APL blasts (Grignani et al., 1993; Altucci and Gronemeyer, 2001) . Despite these observations, precise biological function and mechanism of action of either PML or PML-RARa remain unclear.
Transgenic mice carrying the PML-RARa protein produce an APL-like phenotype (significant latency and an incomplete penetrance) (Insinga et al., 2005) . It was shown that the RARa component is indispensable for its ability to impair hematopoietic terminal differentiation, so RA target genes are thought to represent downstream effectors of PML-RARa. The ability to silence RA target genes depends on its capacity to bind DNA either as homodimers or heterodimers with RXR and PML, recruit chromatin modifiers (HDACs and DNA-methyltransferases -DNMTs) and induce changes in chromatin structure that are not permissive for transcription (Grignani et al., 1998; Lin et al., 1998; Khan et al., 2001; Di Croce et al., 2002; Segalla et al., 2003) . In addition, PML-RARa has different oligomerization characteristics from RARa, it can homodimerize/oligomerize through the coiled-coil region of PML, bind to retinoic acid response elements (RARE) and act as a dominant silencing transcription factor that represses transcription activation mediated by the RAR-RXR heterodimer, which is still produced from the intact RARa allele (Lin and Evans, 2000; Minucci et al., 2000; Altucci and Gronemeyer, 2001) . The interaction of PML-RARa with corepressor/HDAC complexes is responsible for both transcriptional repression of target genes and sensitivity to RA. PML-RARa, in the absence of RA, recruits aberrantly corepressor complexes, such as NCoR, SMRT, mSin3a, HDAC1 or DNMTs, binds to target promoters and represses transcription (Grignani et al., 1998; Khan et al., 2001; Di Croce et al., 2002) . High doses of RA release the corepressor/HDAC complexes from PML-RARa and restores RARa responsiveness of genes involved in myeloid terminal differentiation.
The two major PML-RARa isoforms, while having subtle differences in biological activity and producing slightly different APL phenotypes, have prognostic differences in patients treated with ATRA/chemotherapy combinations. Among newly diagnosed patients, those who expressed the short isoform appeared to have shorter disease-free and overall survival durations than patients who expressed the long isoform (Jurcic et al., 2001; Sucic et al., 2002) . PML-RARa L isoform is expressed in approximately 55% of adult patients with APL, while the S and V isoforms are expressed in approximately 35 and 8% of patients, respectively (Zelent et al., 2001) . In the pediatric population, the V isoform accounts for a larger proportion of cases than in adults (Kane et al., 1996) , with a corresponding decrease in the number of PML-RARa S cases. However, the precise functional differences between these isoforms are not yet clear. Here, we show that in addition to antagonizing the tumor suppressor or the proapoptotic activity of PML, both of which lend the leukemic blasts a marked survival advantage, PML-RARaL, but not PML-RARaS, can directly promote cell growth by transcriptionally activating the pro-proliferative gene, c-fos, in response to growth factor signaling in vitro and in vivo.
Results
Rearrangement between the RARa and PML gene Within the RARa gene, all breakpoints map to genomic sequences lying upstream of exon 4 and as a consequence, the PML-RARa fusion product always contains the same regions of RARa (B-F) containing its DNA and ligand-binding domains. In contrast, the N-terminal PML sequences joined to B-F domains of the RARa show patient-to-patient variability determined by the position of the translocation breakpoint within the PML gene and by alternative exon splicing. Three major breakpoints clusters within the PML gene have been described: intron 3 (bcr3), exon 6 (bcr2) and intron 6 (bcr1) (Figure 1 ). Patients with chromosomal breakpoints in bcr1, bcr2 or bcr3 express either the long (L), the medium (M) or the short (S) isoform of the PML-RARa protein (Pandolfi et al., 1992) . The RNA encoding the PML-RARa L isoform can be alternatively spliced to give PML-RARa M (medium) isoform, which is usually coexpressed with the long isoform in a given patient (Zelent et al., 2001) . Although the transcriptional functions of the PML-RARaS have been well studied, much less is known about the mechanism of action of the long isoform. We sought out to elucidate the transcriptional function of PML-RARaL.
PML-RARa is a potent and specific activator of c-fos promoter By gene array, PML-RARa upregulates 1569 and downregulates another 1726 genes (Alcalay et al., 2003; Park et al., 2003; Nouzova et al., 2004; Meani et al., 2005) . Examples of repressed genes are RARb2 and C/EBPb (Di Croce et al., 2002; Duprez et al., 2003) , while examples of induced genes are Cyclin A1, p21 and c-fos (Casini and Pelicci, 1999; Mu¨ller et al., 2000; Alcalay et al., 2003; Meani et al., 2005) . Given that c-fos gene is involved in proliferation, we hypothesized that part of the function of PML-RARa may be to directly promote cellular growth via transcriptional regulation of c-fos. To investigate the transcriptional effect of PML and PML-RARa on the c-fos promoter, we performed a transient co-transfection assay with c-fos luciferase reporter and either PML or PML-RARaL. PML activated the c-fos luciferase reporter in the absence and in the presence of growth factor signaling and in a dose-dependent manner (about seven-fold over the vector only lane at the highest concentration used, compare lanes 2 and 10) (Figure 2a ), whereas PMLRARa hyper-activated the c-fos promoter in response to growth factor signaling in a dose-dependent manner (about 28-fold increase at the highest concentration, compare lanes 2 and 18) ( Figure 2a ). Importantly, PMLRARa (lanes 19-20) but not PML (lanes 11-12) mediated activation of c-fos was ATRA sensitive. Western blot analysis shows the expression levels of the ectopic proteins (bottom panels). However, after 30 h in the presence of 1 mM ATRA, we could not detect any appreciable degradation of ectopic PML-RARa protein (lanes 19 and 20, bottom panels), due probably to a suboptimal concentration of ATRA used. To test if the PML-RARa activation of c-fos was specific for this promoter, we tested other promoter constructs. We observed that activation by PML-RARa is somewhat specific for c-fos (Figure 2b ). To test whether the effect of PML-RARa is solely via the c-fos promoter or perhaps could also be observed in the context of a potent enhancer, we performed a reporter assay with c-fos promoter fused to the SV40 enhancer. A c-fos promoter construct, pSVOA-D3-c-fos-luc, was stimulated about nine-fold (lane 6, inset), whereas a reporter construct containing the murine c-fos plus the SV40 enhancer, pGL3-Enh-c-fos-luc, showed a 750-fold increase in the presence of PML-RARaL protein and upon growth factor signaling (lane 12). Other reporter constructs, viz, Vb-luciferase and NF-kB-luciferase, showed only marginal induction upon growth factor signaling, respectively, at the highest concentration of PML-RARaL tested (lanes 18 and 30, inset), whereas a control promoter, pFR-Luc (Gal4-dependent), did not exhibit any appreciable effect in the presence of PML-RARaL (lane 24, inset). We conclude that PMLRARaL is a potent and specific activator of the c-fos promoter.
Upregulation of c-fos by PML-RARa is isoform specific (L vs S)
We next tested whether the transcriptional activation of c-fos is mediated by both isoforms. While PML-RARaL isoform activated the c-fos promoter substantially in a dose-dependent fashion, the short isoform failed to do so (Figure 3a) . Moreover, the transcriptional effects of PML-RARaS are also not observed when the c-fos promoter fused to the SV40 enhancer was used (Figure 3b ). Thus, we conclude that the transcriptional activation of c-fos by PML-RARa is isoform specific since it is mediated by the long but not the short isoform.
Upregulation of the endogenous c-fos mRNA by PML-RARa Because c-fos is an immediate early gene that is turned on rapidly upon mitogenic signaling (Thomson et al., 2001; Hazzalin and Mahadevan, 2002) , we tested the kinetics of endogenous c-fos induction by the two isoforms of PML-RARa, both in the absence and in the presence of mitogenic stimulation (20% serum), and further analysed whether the induction of endogenous c-fos is also sensitive to ATRA. The induction of c-fos by PML-RARaL followed the usual kinetics and the gene was maximally expressed at 45 min poststimulation in the presence of both serum and ectopic PML-RARaL (Figure 4) . Although there was some activation by the PML-RARaS isoform, the induction was not above the level achieved by serum stimulation alone. As observed in transient transfection assays, induction of the endogenous c-fos gene by PML-RARa was also sensitive to ATRA since prior treatment of these cells with 2 mM ATRA for 30 h results in substantial reduction of c-fos activation (Figure 4) . A Western blot analysis showed that indeed ATRA treatment led to a significant degradation of both isoforms, although the degradation appears to be more significant for the long isoform (Figure 4, bottom panel) . Taken together, these data suggest that overexpression of PML-RARaL isoform could activate the c-fos gene, but that such activation is ATRA sensitive and, thus, must be caused by the fusion protein.
Acetylated H4 recruitment to the c-fos promoter correlates with activity of PML-RARa isoforms c-fos is an immediate early gene that is basally off but turned on very rapidly after signaling (Thomson et al., 2001; Hazzalin and Mahadevan, 2002) . This rapid response precludes it to be elaborately regulated at the level of chromatin (Alberts et al., 1998; Thomson et al., 2001) . Lack of this constraint together with rapid signalinduced transcriptional response also necessitates an unusual specificity at the level of promoter occupancy. Mechanistically, PML-RARa fusion protein functions in most cases as a potent transcriptional co-repressor by virtue of its tight association with HDAC proteins (Altucci and Gronemeyer, 2001 ). Because there are no known RARE on the c-fos promoter (data not shown), making it unlikely that PML-RARa binds directly to the c-fos promoter, we tested whether the activation of c-fos by PML-RARaL is via indirect mechanisms involving alteration in the chromatin structure. To test this, we analysed the acetylation status of both histone H4 and histone H3 by chromatin immmunoprecipitation (ChIP) assays coupled with real-time PCR in the presence and in the absence of PML-RARa isoforms in a kinetic experiment. The acetylation status of H3 did not change with either isoforms over time, which is consistent with the promoter being relatively open (Figure 5a ). However, dramatic alterations in H4 acetylation were observed over time with PML-RARaL but not PMLRARaS (Figure 5b ). The maximal acetylation was observed 30 min poststimulation, which is when c-fos is maximally induced. While these observations were made with a promoter region overlapping, the serum response element (SRE) (bottom schematics), similar observations were made when a promoter region adjacent to the TATA box was analysed (data not shown), suggesting that changes in the H3 and H4 acetylation status is not localized to one particular region on the c-fos promoter. Thus, PML-RARaL mediates acetylation of H4 on the promoter, thereby rendering it open for transcription.
PML-RARa L interacts physically with HDAC1 and HDAC3
Although it has been shown that PML-RARaS interacts with HDAC1 (Lin et al., 1998; Lin and Evans, 2000; Khan et al., 2001) , the interactions of PML-RARaL with HDAC3 have never been shown. We expressed either Flag-tagged HDAC1 or HDAC3 with PMLRARaS or PML-RARaL isoforms in COS cells and performed an immmunoprecipitation analysis with an anti-RARa antibody. Although expression of HDAC1 was similar to that of HDAC3 ( Figure 6 , top right panel), it was evident that HDAC3 interacts with PMLRARaL much better than HDAC1 (Figure 6 , top left panel). Much weaker interaction of HDAC1 with PMLRARaS was observed and interactions between HDAC3 and PML-RARaS were not tested. Nevertheless, it is clear that PML-RARaL isoform interacts strongly with HDAC3 and to a lesser extent with HDAC1. Furthermore, the long isoform interacts better with HDAC1 compared to the short isoform.
HDAC3 is recruited to the c-fos promoter and its kinetics correlates with the activity of PML-RARa isoforms PML-RARa retains both DNA and ligand binding domains of RARa, and thus inhibits its transcriptional function through aberrant recruitment of co-repressors and HDACs (Salomoni and Pandolfi, 2002) . To address how might PML-RARaL induce acetylation of H4 and possible recruitment of HDACs, we analysed the kinetics of HDAC3 recruitment to the c-fos promoter in the presence of PML-RARa isoforms. Interestingly, we observed that PML-RARaL but not PML-RARaS induced recruitment of HDAC3 at the c-fos promoter 15-min postsimulation, but that recruitment is abolished by 30 min (Figure 7a ). There was also an enhanced, albeit less, recruitment of HDAC3 to the promoter by PML-RARaS at 45-min poststimulation. To further test the functional involvement of HDAC3, we cotransfected PML-RARaL and HDAC3 in the absence and in the presence of trichostatin A (TSA). The PML-RARaL mediated activation of the c-fos promoter was dramatically enhanced in the presence of TSA, which inhibits HDAC activity (Figure 7b) . Conversely, HDAC3 expression resulted in inhibition of the c-fos activity.
Role of SRE on c-fos promoter in PML-RARaL activity
To investigate if SRE plays a role in PML-RARaL mediated activation of the c-fos promoter, we performed a transient co-transfection assay with a luciferase promoter construct that contains five SRE sites upstream of a TATA box and either PML-RARaS or PML-RARaL (1mg). PML-RARaL but not (Figure 8a) . Importantly, PML-RARaL activity on c-fos was also inhibited upon ectopic expression of HDAC3 (compare lanes 6 and 12). To further test the role of the SRE site within the c-fos promoter, we performed a transient cotransfection assay using a c-fos luciferase construct that contains a mutated SRE (SRE-ST) (Kim et al., 1998) and either PML-RARaS or PML-RARaL (1 mg). As expected, neither isoforms activated this reporter construct (Figure 8b ).
Discussion
Leukemic cells are characterized by arrest of differentiation at a specific stage compatible with continued proliferation and enhanced resistant to stress. Accordingly, the consequence of the formation of PML-RARa in APL is a block of differentiation at the promyelocytic stage. It is reasonable to assume that the altered functionality of PML in the fusion protein, such as loss of its pro-apoptotic activity or abrogation of its correpressor function, adds to the growth potential or survival capacity of APL blast, whereas HDACdependent silencing of normal retinoid signaling during myelopoiesis causes the differentiation block (Altucci and Gronemeyer, 2001 ). PML-RARa induces DNA hypermethylation and heterochromatin formation through aberrant recruitment of different chromatin modifying enzymes to specific promoters, leading to its transcriptional silencing. But PML-RARa also has been shown to upregulate a number of genes on different microarray setups (Alcalay et al., 2003; Park et al., 2003; Nouzova et al., 2004; Meani et al., 2005) . Either PMLRARa has acquired new DNA-binding properties different from those of the RARa (Hauksdottir and Privalsky, 2001 ) such that it does not only bind to RAREs, or it can also upregulate target genes through indirect mechanisms (Duprez et al., 2003; Duprez, 2004) . Thus, the transcriptional activity of PML-RARa in the absence of specific RARE sequences in most of the myeloid gene promoters and the c-fos promoter can Figure 6 PML-RARa L isoform interacts physically with HDAC1 and HDAC3. Whole-cell extracts of COS7 cells transfected with either FLAG-HDAC1 (7 mg) or FLAG-HDAC3 (13 mg) alone or plus PML-RARaL (20 mg) or PML-RARaS (12 mg) isoform were subjected to immunoprecipitation with anti-RARa antibody. Immunoprecitations with anti-RARa antibody developed first, with a-FLAG antibody (a-FLAG) (top) and then stripped and reprobed with anti-RARa antibody (a-RARa) (bottom). Western blots of whole-cell extracts probed with anti-FLAG antibody (a-FLAG) (top), stripped and reprobed with anti-RARa antibody (a-RARa) (bottom). be explained. Consistent with an indirect mechanism, we show that the PML-RARa long isoform can stimulate the c-fos promoter via its antirepressor activity.
RARa is a member of the superfamily of nuclear hormone receptors (Soprano et al., 2004) . It binds to specific RAR elements (RARE) as heterodimer with retinoid X receptors (RXR). Retinoic acid (RA) modulates the activity of RARa/RXR. In the absence of RA, RARa/RXR recruits repressor complexes (SMRT/mSin3a/HDAC1) and represses target genes. In the presence of physiological levels of RA, corepressor complexes are released and the receptor associates with transcriptional coactivators (PML, ATP-dependent chromatin remodeling complexes, HATs and RNA polymerase II) to transactivate target genes critical for the induction of myelod terminal differentiation.
In general, PML-RARa acts as a dominant-negative of RARa activities. In the case of AP-1 transcriptional activity, where usually RARa is a potent RA-dependent inhibitor of AP-1, PML-RARa transforms into a RA-dependent activator of AP-1 (Doucas et al., 1993) . Given that AP-1 consists of fos and jun, it is likely that the effects seen before are due to activation of c-fos. However, PML-RARa acts not only as a dominantnegative of RARa but also of PML activities. For instance, it has been shown that wild-type PML acts as a cofactor of p53, favors its post-transcriptional modifications (phosphorylation and acetylation) and enhances its activity. Inactivating p53 mutations are the most common genetic alteration found in human cancers; however, mutations in p53 are extremely rare in APL. Nevertheless, it was found that PML-RARa associates with p53 and, by recruitment of HDAC, causes deacetylation and subsequent degradation/inhibition of p53 via the proteasome/Mdm2 pathway in hematopoietic precursors. PML-RARa induced p53 deacetylation/ degradation results in downregulation of p53 dependent transcription and inhibition of p53-dependent stress responses (Insinga et al., 2004) . PML-RARa expression in primary hematopoietic cells enhances survival under conditions of various p53-dependent stresses and this effect depends on the presence of wt PML (Insinga et al., 2004,) . Inhibition of p53 is achieved by the capacity of PML-RARa to associate with the product of the remaining wild-type PML allele. PML acts as a molecular bridge between p53 and the PML-RARa fusion protein. Enhanced survival of primary hematopoietic cells upon expression of PML-RARa is in contrast to what was found previously in a wide number of cell lines (including hematopoietic cell lines), where PML-RARa expression lead to apoptosis rather than enhanced survival (Ferrucci et al., 1997) . While the biological functions of PML-RARa are well studied, mechanisms of its action are less clear. This is compounded by the fact that there are several alternatively spliced isoforms of PML-RARa. Most of what is known in the literature regarding the function of PML-RARa is for the short isoform. Given the fact that 55% of the APL patients exhibit the long isoform, we became interested in deciphering its transcription functions. Our results suggest a novel pro-proliferative function for PML-RARaL via activation of the c-fos gene, which is sensitive to both ATRA and TSA. This is important since ATRA and TSA (HDAC inhibitor) restores terminal differentiation and remission of APL phenotype. However, we wish to emphasize that ATRA/ chemotherapy is used largely as a postremission treatment and currently arsenic trioxide (ATO) is considered the treatment of choice for patients with relapsed disease. One of the surprising aspects of our model (Figure 9 ) is that PML-RARaL first induces recruitment of HDAC3 to the c-fos promoter before induction of the gene begins. Subsequently, HDAC3 recruitment to the promoter is abolished when maximal activation of the gene ensues with. Given that PML-RARaL interacts strongly with HDAC3, we propose that PML-RARaL removes HDAC3 from the promoter, which allows acetylation of H4 and concomitant recruitment of signal-induced activators like TFII-I and SRF (Figure 9 ). Because HDAC3 has specificity for H4K5, upon removal of HDAC3 by PML-RARaL in the presence of serum, a rapid reversal of H4 acetylation can be expected (Codina et al., 2005; Hartman et al., 2005) . Our results suggest an antirepressor activity for PML-RARaL rather than a direct activation function. Removal of HDAC3 in response to growth factor signaling could thus, allow recruitment of co-activators like CBP/p300, which is known to interact with Elk/ TCF and be recruited to the c-fos promoter (Nissen et al., 2001; Li et al., 2003) . We believe this is a highly coordinated process since it is specific for c-fos but could be true for other promoters where PML-RARaL has indirect stimulatory effect, like on AP-1 responsive promoters (Doucas et al., 1993) . In this context, SRF must also play an important role in coordinating these responses since PML-RARa mediated activation of the c-fos promoter appears largely via the SRE. The precise reason for c-fos promoter selectivity by PML-RARaL is currently unknown and elucidation of this mechanism will be a challenge for the future. Our results suggest a novel pro-proliferative function for PML-RARaL via activation of the c-fos gene and predicts an increased cellularity in patients that carry this isoform, although precise and accurate analysis will be needed.
Materials and methods
Cell culture and plasmids NIH3T3 and COS7 cells were grown under standard conditions. The pCMV-Tag2-FLAG-PML and pCMV-Tag2B-FLAG-PML-RARaS vectors were obtained from Dr Pier Paolo Pandolfi (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) and pCGN-PML-RARaL from Dr Donald Bloch (Massachussets General Hospital, Boston, MA, USA).
Transient transfections and reporter assays
Transfections in NIH3T3 (Figures 4, 5 and 7) and COS7 (Figures 2, 3, 6 and 8) cells were carried out with Polyfect (Qiagen) or Fugene (Roche) and Lipofectamine (Invitrogen), respectively. For reporter assays, cells were serum-starved for 14-16 h and stimulated with 20% serum for 4 h. The luciferase reporter constructs used are: pSVOA-D5-c-fos-luc, containing the wild-type murine c-fos promoter; pGL3-Enh-c-fos-luc, containing an SV40 enhancer and the wild-type murine c-fos promoter; pSVOA-D5-(SRE-ST)-c-fos-luc, containing the murine c-fos promoter with a mutated SRE site (SRE-ST: 5 0 GGATATTACC3 0 ) (Kim et al., 1998) and, p(SRE) 5 -luc, containing only five SREs in tandem (Stratagene). Luciferase activity was assessed using the Dual Luciferase kit (Promega).
Chromatin immunoprecipitation (ChIP) NIH3T3 cells were transfected with PML-RARa L or S isoform and 22 h later, cells were serum starved for 43 h and then, serum stimulated with DMEM/20% FCS for 0, 15, 30, 45 and 60 min. Cells were fixed directly by adding formaldehyde to a final concentration of 1% for 10 min at room temperature. ChIP assays were performed according to the protocol of Chromatin Immunoprecipitation Assay Kit (Upstate Biotechnology Inc., Lake Placid, New York, USA) with minor modifications. Fixation was stopped by incubation with a final concentration of 0.125 M glycine for 5 min, and elution from the beads was performed twice at 651C for 15 min. Anti-acetyl-histone H3 (Cat. No. 06-599, 5 ml), anti-acetyl-H4 (Cat. No. 06-866, 4 ml) were from Upstate Biotechnology Inc. Anti-HDAC3 (H-99, 5 ml) was from Santa Figure 9 Model of c-fos activation by PML-RARa. HDAC activity is partially responsible for keeping basal expression levels of c-fos low or off. In the presence of PML-RARa and within the first 15 min of 20% serum stimulation, more HDAC3 is recruited to the c-fos promoter but within the next 15 min (30 min post-stimulation), PML-RARa binds to the recruited HDAC3, strip off the deacetylase activity from the c-fos promoter, and thus favor opening of the chromatin as a result of increased recruitment of AcH4 and probably increased recruitment of HAT activity. This acetylation leads, presumably, to a more open chromatin structure and facilitates transcription initiation by RNA polymerase II.
Cruz Biotechnology, Inc. DNA samples from ChIP assays were analysed by real-time PCR using a GeneAmp 5700 instrument and Amplitaq PCR master mix (Applied Biosystems, Branchburg, NJ, USA). The sequences of the real-time PCR primers were as follows: c-fos1 5 0 CCTTTACACAG GATGTCCATATTAGGA 3 0 , 5 0 CGTGTAGGATTTCGGA GATGGT 3 0 ; amylase 5 0 GCTTTCCCTCATTGGGTTCTG 3 0 , 5 0 CGCTCACATTCCTTGGCAATAT 3 0 . The sequences of the Taqman probes were: c-fos1 5 0 6FAM TGCGTCAGCA GGTTT-MGBNFQ 3 0 and amylase, 5 0 6FAM-CCTGTTCGA GTGGCGCTGGGTT-MGBNFQ 3 0 . Primers and probe for rodent GAPDH were purchased from Applied Biosystems (P/N 4308313). Relative fold induction is expressed as the ratio of cfos1/amylase or cfos1/gapdh, calculated both, as % of input that was immunoprecipitated. Amylase, a pancreatic specific gene, was used as a control for the recruitment of acetylated histones and GAPDH, a housekeeping gene, was used as a control for the recruitment of HDAC3.
Real-time RT-PCR RNA was prepared using the RNeasy kit from Qiagen and cDNA was prepared in 20 ml out of 1 mg of total RNA using the Taqman Reverse Transcription Reagents from Applied Biosystems (P/N N808-0234). The sequences of the c-fos realtime RT-PCR primers were 5 0 ATCCGAAGGGAACGGAA TAAG 3 0 and 5 0 CAACGCAGACTTCTCATCTTCAA 3 0 . The sequence of the c-fos RT Taqman probe was 5 0 6FAM-TCCAAGCGGAGACAGA-MGBNFQ 3 0 . The primers and probe for eukaryotic 18S rRNA were purchased from Applied Biosystems (P/N 4319413). Relative fold induction is expressed as the ratio of cfos1/18S.
